Omecamtiv mecarbil, a cardiac myosin activator or cardiac myotrope, has been granted Fast Track designation by the FDA for treatment of HFrEF patients.
This study showed that a SBP of 120 to 129 mmHg was associated with the lowest risk of adverse outcomes in HFpEF. SBP lowering does not explain the treatment effects of sacubitril/valsartan.
The FDA approved dapagliflozin for treatment of heart failure patients with reduced ejection fraction to reduce CV death and hospitalization for HF.
In a study of acute HF patients in a Korean registry, AF was more prevalent with increasing EF, and associated with increased CV and total mortality in HFpEF patients and increased risk of stroke in HFrEF and HFpEF patients.
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.
This series aims to provide cardiologists and other health care professionals involved in the management of heart failure patients a well-balanced expert view on findings of the PARAGON-HF and other trials, with implications for the whole ejection fraction range. Member registration (free) is needed to enroll in this course.
ACC 2020 This post-hoc analysis of the DAPA-HF trial showed a consistent treatment benefit of dapagliflozin in HFrEF patients compared with placebo, regardless of background therapy.
ACC 2020 Jonathan Cunningham shares three major findings from a subanalysis of the PARAGON-HF trial in HFpEF patients.
ACC 2020 A subanalysis of the PARAGON-HF trial demonstrated that treatment with the ARNI sacubitril/valsartan reduced NT-proBNP levels with 19% compared to valsartan alone in HFpEF.
ACC 2020 The soluble guanylate cyclase stimulator vericiguat reduced CV death and HF hospitalization compared to placebo in HFrEF patients with worsening HF.